Cambridge Investment Research Advisors
MLAB icon

Cambridge Investment Research Advisors’s Mesa Laboratories MLAB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MLAB Stock Details MLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,252
Closed -$212K – 3802
2025
Q2 		$212K Sell
2,252
-44
-2% -$4.83K ﹤0.01% 3304
2025
Q1 		$272K Sell
2,296
-119
-5% -$16.2K ﹤0.01% 2951
2024
Q4 		$319K Sell
2,415
-578
-19% -$71K ﹤0.01% 2786
2024
Q3 		$389K Sell
2,993
-347
-10% -$40.8K ﹤0.01% 2618
2024
Q2 		$290K Sell
3,340
-915
-22% -$95.8K ﹤0.01% 2729
2024
Q1 		$467K Sell
4,255
-663
-13% -$66.8K ﹤0.01% 2331
2023
Q4 		$515K Sell
4,918
-820
-14% -$79.9K ﹤0.01% 2155
2023
Q3 		$603K Sell
5,738
-22
-0.4% -$2.82K ﹤0.01% 1936
2023
Q2 		$740K Buy
5,760
+313
+6% +$47.7K ﹤0.01% 1830
2023
Q1 		$952K Buy
5,447
+109
+2% +$19.5K ﹤0.01% 1606
2022
Q4 		$887K Buy
5,338
+114
+2% +$17.9K ﹤0.01% 1596
2022
Q3 		$736K Buy
5,224
+285
+6% +$52K ﹤0.01% 1683
2022
Q2 		$1.01M Buy
4,939
+81
+2% +$17.7K 0.01% 1480
2022
Q1 		$1.24M Sell
4,858
-27
-0.6% -$7.33K 0.01% 1425
2021
Q4 		$1.6M Buy
4,885
+755
+18% +$237K 0.01% 1279
2021
Q3 		$1.25M Buy
4,130
+202
+5% +$57.4K 0.01% 1371
2021
Q2 		$1.06M Buy
3,928
+130
+3% +$33K 0.01% 1487
2021
Q1 		$925K Buy
3,798
+149
+4% +$41K 0.01% 1479
2020
Q4 		$1.05M Buy
3,649
+188
+5% +$51.7K 0.01% 1277
2020
Q3 		$882K Buy
3,461
+241
+7% +$57.3K 0.01% 1257
2020
Q2 		$698K Buy
3,220
+404
+14% +$93.1K 0.01% 1346
2020
Q1 		$637K Buy
2,816
+602
+27% +$148K 0.01% 1231
2019
Q4 		$552K Buy
2,214
+25
+1% +$5.86K ﹤0.01% 1516
2019
Q3 		$520K Buy
2,189
+69
+3% +$16K ﹤0.01% 1471
2019
Q2 		$518K Buy
2,120
+93
+5% +$21.7K ﹤0.01% 1397
2019
Q1 		$467K Buy
2,027
+157
+8% +$35.5K ﹤0.01% 1524
2018
Q4 		$390K Hold
1,870
– – ﹤0.01% 1469
2018
Q3 		$347K Sell
1,870
-1,932
-51% -$389K ﹤0.01% 1701
2018
Q2 		$803K Buy
3,802
+2,082
+121% +$364K 0.01% 1104
2018
Q1 		$255K Buy
+1,720
New +$234K ﹤0.01% 1791
2017
Q4 		– Sell
-1,533
Closed -$229K – 2133
2017
Q3 		$229K Buy
1,533
+68
+5% +$9.59K ﹤0.01% 1736
2017
Q2 		$210K Sell
1,465
-194
-12% -$27.6K ﹤0.01% 1726
2017
Q1 		$204K Buy
1,659
+1
+0.1% +$122 ﹤0.01% 1598
2016
Q4 		$204K Buy
+1,658
New +$207K ﹤0.01% 1487

Other funds holding MLAB

CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
SCM
Simcoe Capital Management New York $576M AUM 36.22% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Cambridge Investment Research Advisors's MLAB Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Mesa Laboratories (MLAB) in Q3 2025, closing a stake of 2,252 shares — an estimated $212K sold.

Cambridge Investment Research Advisors first reported a position in MLAB in Q4 2016 and held it in 34 quarters. The position peaked at $1.6M in Q4 2021. 141 funds tracked by Wall St. Rank hold MLAB as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining Mesa Laboratories position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,252 Mesa Laboratories shares in Q3 2025, an estimated $212K.
  • Cambridge Investment Research Advisors first reported a position in Mesa Laboratories in Q4 2016 and held it in 34 quarters.
  • Cambridge Investment Research Advisors's Mesa Laboratories position peaked at $1.6M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Mesa Laboratories as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.